SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 56.98+1.1%Nov 5 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Aloner3/13/2023 2:50:17 PM
3 Recommendations

Recommended By
DewDiligence_on_SI
OldAIMGuy
The Ox

   of 52153
 
PRVB to be acquired by Sanofi at $25.00/Share, up 258% today

Sanofi SA (NASDAQ: SNY) has agreed to acquire Provention Bio Inc (NASDAQ: PRVB) for $25.00 per share in cash, representing an equity value of approximately $2.9 billion.

The transaction adds a type 1 diabetes therapy to Sanofi's core asset portfolio in General Medicines, and further drives its strategic shift toward products with a differentiated profile.

In November 2022, the FDA approved Tzield (teplizumab-mzwv) to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years and older with stage 2 type 1 diabetes.

The purchase builds on an existing co-promotion agreement with Provention Bio, already delivering Tzield to patients needing this immune-mediated therapy.

Tzield is also in late-stage clinical development for pediatric and adolescent patients newly diagnosed with clinical T1D (Stage 3).

A Phase 3 trial, PROTECT, is underway, and top-line results are expected in the second half of 2023.

Additional opportunities for TZIELD include re-dosing and formulations and new therapeutic indications.

Sanofi currently expects to complete the acquisition in the second quarter of 2023.

Price Action: PRVB shares are up 257.90% at $23.98 on the last check Monday.

Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News